- ICH GCP
- US Clinical Trials Registry
- Search trials
Søg i kliniske forsøg efter: Treprizolizumab; Tirelizumab; Carellizumab; Sintilimab;
I alt 431 resultater
-
RenJi HospitalIkke rekrutterer endnuTredjelinjes behandling | Avanceret duodenalt adenokarcinom | Furquinelone kombineret med sintilimab
-
Xiaorong DongUkendtHjernemetastaser | NSCLC trin IV | Sintilimab | SRSKina
-
West China HospitalSichuan Provincial People's Hospital; The First People's Hospital of Ziyang og andre samarbejdspartnereIkke rekrutterer endnu
-
Shandong Cancer Hospital and InstituteRekruttering
-
Zhejiang Cancer HospitalRekrutteringEsophageal pladecellekarcinomKina
-
Second Affiliated Hospital of Guangzhou Medical...Rekruttering
-
Innovent Biologics (Suzhou) Co. Ltd.Afsluttet
-
Tianjin Medical University Cancer Institute and...Ikke rekrutterer endnu
-
Innovent Biologics (Suzhou) Co. Ltd.AfsluttetSunde mandlige emnerKina
-
Innovent Biologics (Suzhou) Co. Ltd.RekrutteringAvanceret galdevejskræftKina
-
Second Affiliated Hospital of Guangzhou Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... og andre samarbejdspartnereAktiv, ikke rekrutterendeHepatocellulært karcinom Ikke-operabeltKina
-
The First Hospital of Jilin UniversityIkke rekrutterer endnuLokalt avanceret endetarmskræft | Anti-PD-1 | Total Neoadjuverende behandlingKina
-
Hebei Medical University Fourth HospitalRekruttering
-
Shanghai YingLi Pharmaceutical Co. Ltd.RekrutteringAvancerede solide tumorerKina
-
Zhou ChengzhiUkendtLungekræft | Primary Pulmonary Lymphoepithelioma-like CarcinomaKina
-
Beijing Tiantan HospitalRekrutteringMeningiom, ondartetKina
-
Qianfoshan HospitalRekrutteringAvanceret ikke-pladeepitel, ikke-småcellet lungekræftKina
-
Innovent Biologics (Suzhou) Co. Ltd.Rekruttering
-
RemeGen Co., Ltd.RekrutteringAvancerede solide tumorerKina
-
Tang-Du HospitalAktiv, ikke rekrutterendeNeoadjuverende PD-1-hæmmer, Anlotinib kombineret med kemoterapi i resektabelt stadium IIA-IIIB NSCLCLungekræft | Kemoterapi | Sintilimab | AnlotinibKina
-
The First People's Hospital of ChangzhouIkke rekrutterer endnuKolorektal cancer metastatisk
-
Fujian Medical University Union HospitalIkke rekrutterer endnuEsophageal pladecellecarcinom Thoracic Stadium II | Esophageal pladecellecarcinom Thoracic Stadium III | Esophageal pladecellecarcinom Thoracic Stadium IVKina
-
Innovent Biologics (Suzhou) Co. Ltd.AfsluttetAvanceret eller metastatisk NSCLCKina
-
jianming xuNeoCuraRekruttering
-
Shandong Cancer Hospital and InstituteIkke rekrutterer endnu
-
Jiangsu Simcere Biologics Co., LtdRekrutteringAvanceret solid tumor | Kutan T-celle lymfomKina
-
Second Affiliated Hospital, School of Medicine,...Aktiv, ikke rekrutterendeIkke-småcellet lungekræftKina
-
Tianjin Medical University Cancer Institute and...RekrutteringSintilimab, Cetuximab, Regorafenib, Combine, mCRCKina
-
Sun Yat-sen UniversityIkke rekrutterer endnuAngioimmunoblastisk T-celle lymfomKina
-
West China HospitalAktiv, ikke rekrutterendeKarcinom, nyrecelle | Immunterapi | Fumarate Hydratase mangelKina
-
The First Affiliated Hospital of Zhengzhou UniversityIkke rekrutterer endnuEsophageal pladecellekarcinom (ESCC) | PD-1 hæmmereKina
-
Second Affiliated Hospital, School of Medicine,...AfsluttetResecerbar NSCLC med høj risikoKina
-
Innovent Biologics (Suzhou) Co. Ltd.Afsluttet
-
Innovent Biologics (Suzhou) Co. Ltd.Innovent Biologics (USA), Inc.Trukket tilbageMetastatisk kutan melanom | Uoperabelt kutan melanomForenede Stater, Tyskland, Frankrig, Australien, Spanien, Schweiz, Det Forenede Kongerige
-
Zhejiang Cancer HospitalAfsluttet
-
Wuhan UniversityRekrutteringEsophageal pladecellekarcinomKina
-
Sun Yat-sen UniversityInnovent Biologics (Suzhou) Co. Ltd.Ukendt
-
Changzhou Cancer Hospital of Soochow UniversityUkendt
-
West China HospitalIkke rekrutterer endnu
-
Zhejiang Cancer HospitalIkke rekrutterer endnuSpiserørskræft | Ældre patienter | Immunterapi | Sintilimab | Kemoradioterapi
-
Peking Union Medical College HospitalRekruttering
-
The First Hospital of Jilin UniversityAktiv, ikke rekrutterendeLokalt avanceret endetarmskræft | PD-1 | Total Neoadjuverende behandling | TislelizumabKina
-
Innovent Biologics (Suzhou) Co. Ltd.Afsluttet
-
Sichuan Cancer Hospital and Research InstituteInnovent Biologics, Inc.UkendtNeoplasmer | Luftvejssygdomme | Lungesygdomme | Thoracale neoplasmer | Ikke-småcellet lungekræft
-
Nanfang Hospital of Southern Medical UniversityIkke rekrutterer endnuIkke-operabelt hepatocellulært karcinom
-
Shanghai Children's Medical CenterIkke rekrutterer endnuTilbagevendende trin IV højrisiko neuroblastomKina
-
West China HospitalIkke rekrutterer endnuNyrecellekarcinom | Sintilimab | FH-mangelfuld
-
M.D. Anderson Cancer CenterInnovent Biologics (Suzhou) Co. Ltd.Aktiv, ikke rekrutterende
-
Henan Cancer HospitalAktiv, ikke rekrutterendeEsophageal pladecellekarcinomKina
-
Innovent Biologics (Suzhou) Co. Ltd.Ikke rekrutterer endnu